Admilparant Phase 3 trial hits goal, but one dose misses
Bristol Myers Squibb's admilparant Phase 3 trial met its...
23andMe Bankruptcy Shakes Biotech Sector as Early Warning Signs Go Unheeded
The recent bankruptcy filing of 23andMe has sent ripples...